메뉴 건너뛰기




Volumn 22, Issue 9, 2008, Pages 1658-1664

Immunotherapy for myeloid leukemias: Current status and future directions

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; BUSULFAN; CANCER VACCINE; CYCLOPHOSPHAMIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN 70; IMATINIB; LEUKEMIA ANTIGEN; MONTANIDE ISA 51; QS 21; WT1 PROTEIN;

EID: 51649129479     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.148     Document Type: Review
Times cited : (19)

References (60)
  • 1
    • 0032428533 scopus 로고    scopus 로고
    • Surface marker abnormalities in myelodysplastic syndromes
    • Elghetany MT. Surface marker abnormalities in myelodysplastic syndromes. Hematologica 1998; 83: 1104-1115.
    • (1998) Hematologica , vol.83 , pp. 1104-1115
    • Elghetany, M.T.1
  • 2
    • 15744378112 scopus 로고    scopus 로고
    • Immunophenotyping of acute leukemias
    • Bene MC. Immunophenotyping of acute leukemias. Immunol Lett 2005; 98: 9-21.
    • (2005) Immunol Lett , vol.98 , pp. 9-21
    • Bene, M.C.1
  • 3
    • 0035874549 scopus 로고    scopus 로고
    • Targeting of B7-1 (CD80) immunoglobulin G fusion protein to acute myeloid leukemia blasts increases their costimulatory activity for autologous remission T cells
    • Notter M, Willinger T, Erben U, Thiel E. Targeting of B7-1 (CD80) immunoglobulin G fusion protein to acute myeloid leukemia blasts increases their costimulatory activity for autologous remission T cells. Blood 2001; 97: 3138-3145.
    • (2001) Blood , vol.97 , pp. 3138-3145
    • Notter, M.1    Willinger, T.2    Erben, U.3    Thiel, E.4
  • 4
    • 0032840063 scopus 로고    scopus 로고
    • Acute myelogenous leukemia blasts as accessory cells during T lymphocyte activation: Possible implications for future therapeutic strategies
    • Bruserud O. Acute myelogenous leukemia blasts as accessory cells during T lymphocyte activation: Possible implications for future therapeutic strategies. Leukemia 1999; 13: 1175-1178.
    • (1999) Leukemia , vol.13 , pp. 1175-1178
    • Bruserud, O.1
  • 5
    • 0026688428 scopus 로고
    • Hematopoietic cytokines inhibit apoptosis induced by transforming growth factor beta 1 and cancer chemotherapy compounds in myeloid leukemia cells
    • Lotem J, Sachs L. Hematopoietic cytokines inhibit apoptosis induced by transforming growth factor beta 1 and cancer chemotherapy compounds in myeloid leukemia cells. Blood 1992; 80: 1750-1757.
    • (1992) Blood , vol.80 , pp. 1750-1757
    • Lotem, J.1    Sachs, L.2
  • 6
    • 36049003710 scopus 로고    scopus 로고
    • Potential target antigens for immunotherapy identified by serological expression cloning (SEREX)
    • Jager D. Potential target antigens for immunotherapy identified by serological expression cloning (SEREX). Methods Mol Biol 2007; 360:319-326.
    • (2007) Methods Mol Biol , vol.360 , pp. 319-326
    • Jager, D.1
  • 7
    • 0026091624 scopus 로고
    • The molecular pathology of chronic myelogengus leukemia
    • Kurzrock R, Talpaz M. The molecular pathology of chronic myelogengus leukemia. Br J Hematol 1991; 79: 34-37.
    • (1991) Br J Hematol , vol.79 , pp. 34-37
    • Kurzrock, R.1    Talpaz, M.2
  • 9
    • 0029002248 scopus 로고
    • Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules
    • Bocchia M, Wentworth PA, Southwood S, Sidney J, McGraw K, Scheinberg DA et al. Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules. Blood 1995; 85: 2680-2684.
    • (1995) Blood , vol.85 , pp. 2680-2684
    • Bocchia, M.1    Wentworth, P.A.2    Southwood, S.3    Sidney, J.4    McGraw, K.5    Scheinberg, D.A.6
  • 10
    • 0029870222 scopus 로고    scopus 로고
    • Specific human cellular immunity to bcr-abl-oncogene-derived peptides
    • Bocchia M, Korontsvit T, Xu Q, Mackinnon S, Yang SY, Sette A et al Specific human cellular immunity to bcr-abl-oncogene-derived peptides. Blood 1996; 87: 3187-3392.
    • (1996) Blood , vol.87 , pp. 3187-3392
    • Bocchia, M.1    Korontsvit, T.2    Xu, Q.3    Mackinnon, S.4    Yang, S.Y.5    Sette, A.6
  • 11
    • 0035892131 scopus 로고    scopus 로고
    • Direct evidence that leukemia cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein
    • Clark RE, Dodi IA, Hill SC, Lill JR, Aubert G, Macintyre AR et al. Direct evidence that leukemia cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein. Blood 2001; 98: 2887-2893.
    • (2001) Blood , vol.98 , pp. 2887-2893
    • Clark, R.E.1    Dodi, I.A.2    Hill, S.C.3    Lill, J.R.4    Aubert, G.5    Macintyre, A.R.6
  • 12
    • 20444378186 scopus 로고    scopus 로고
    • Ex vivo characterization of multiepitopic tumor specific CD8 T cells in patients with chronic myeloid leukemia: Implications for vaccine development and cellular immunotherapy
    • Gannage M, Abel M, Michaellet AS, Delluc S, Iambert M, Giraudier S et al. Ex vivo characterization of multiepitopic tumor specific CD8 T cells in patients with chronic myeloid leukemia: Implications for vaccine development and cellular immunotherapy. J Immunol 2005; 174: 8210-8218.
    • (2005) J Immunol , vol.174 , pp. 8210-8218
    • Gannage, M.1    Abel, M.2    Michaellet, A.S.3    Delluc, S.4    Iambert, M.5    Giraudier, S.6
  • 13
    • 0034161533 scopus 로고    scopus 로고
    • Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint peptides generates specific immune responses
    • Pinilla-Ibarz J, Cathcart K, Krontsvit T, Soignet S, Bocchia M, Caggiano J et al. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint peptides generates specific immune responses. Blood 2000; 95: 1781-1787.
    • (2000) Blood , vol.95 , pp. 1781-1787
    • Pinilla-Ibarz, J.1    Cathcart, K.2    Krontsvit, T.3    Soignet, S.4    Bocchia, M.5    Caggiano, J.6
  • 14
    • 0026560593 scopus 로고
    • The translocation (6;9) associated with a specific subtype of acute myeloid leukemia, results in the fusion of two genes, dek and can, and the expression of a chimeric, leukemia specific dek-can mRNA
    • von Lindern M, Fornerod M, van Baal S, Jaegle M, de Wit T, Buijs A et al. The translocation (6;9) associated with a specific subtype of acute myeloid leukemia, results in the fusion of two genes, dek and can, and the expression of a chimeric, leukemia specific dek-can mRNA. Mol Cell Biol 1992; 12: 1687-1697.
    • (1992) Mol Cell Biol , vol.12 , pp. 1687-1697
    • von Lindern, M.1    Fornerod, M.2    van Baal, S.3    Jaegle, M.4    de Wit, T.5    Buijs, A.6
  • 15
    • 0025875679 scopus 로고    scopus 로고
    • de The' H, Lavau C, Marchino A, Chomienne C, Degos L, Dejean A. The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 1991; 66: 675-684.
    • de The' H, Lavau C, Marchino A, Chomienne C, Degos L, Dejean A. The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 1991; 66: 675-684.
  • 16
    • 0027180828 scopus 로고
    • An AML1/ETO fusion transcript is consistently detected by RNA based polymerase chain reaction in acute myelogenous leukemia containing the (8;21)(q22;q22) translocation
    • Downing JR, Head Dr, Curcio-Brint AM, Hulshof MG, Motroni TA, Raimondi SC et al. An AML1/ETO fusion transcript is consistently detected by RNA based polymerase chain reaction in acute myelogenous leukemia containing the (8;21)(q22;q22) translocation. Blood 1993; 81 2860-2865.
    • (1993) Blood , vol.81 , pp. 2860-2865
    • Downing, J.R.1    Head, D.2    Curcio-Brint, A.M.3    Hulshof, M.G.4    Motroni, T.A.5    Raimondi, S.C.6
  • 17
    • 0027403209 scopus 로고
    • Human CD4 lymphocytes specifically recognize a peptide representing a fusion region of the hybrid protein pml/RARalpha present in acute promyelocytic leukemia cells
    • Gambacorti-Passerini C, Grignani F, Arienti F, Pandolfi PP, Pelicci PG, Parmiani G. Human CD4 lymphocytes specifically recognize a peptide representing a fusion region of the hybrid protein pml/RARalpha present in acute promyelocytic leukemia cells. Blood 1993; 81: 1369-1375.
    • (1993) Blood , vol.81 , pp. 1369-1375
    • Gambacorti-Passerini, C.1    Grignani, F.2    Arienti, F.3    Pandolfi, P.P.4    Pelicci, P.G.5    Parmiani, G.6
  • 18
    • 0026644858 scopus 로고
    • Structure, chromosomal assignment, and expression of the gene for proteinase-3. The Wegener's granulomatosis autoantigen
    • Sturrock AB, Franklin KF, Rao G, Marshall BC, Rebentisch MB, Lemons RS et al. Structure, chromosomal assignment, and expression of the gene for proteinase-3. The Wegener's granulomatosis autoantigen. J Biol Chem 1992; 267: 1193-1199.
    • (1992) J Biol Chem , vol.267 , pp. 1193-1199
    • Sturrock, A.B.1    Franklin, K.F.2    Rao, G.3    Marshall, B.C.4    Rebentisch, M.B.5    Lemons, R.S.6
  • 19
    • 0028213154 scopus 로고
    • Myeloblastin/proteinase 3 belongs to the set of negatively regulated primary response genes expressed during in vitro myeloid differentiation
    • Chen T, Meier R, Ziemiecki A, Fey MF, Tobler A. Myeloblastin/proteinase 3 belongs to the set of negatively regulated primary response genes expressed during in vitro myeloid differentiation. Biochem Biophys Res Commun 1994; 200: 1130-1135.
    • (1994) Biochem Biophys Res Commun , vol.200 , pp. 1130-1135
    • Chen, T.1    Meier, R.2    Ziemiecki, A.3    Fey, M.F.4    Tobler, A.5
  • 20
    • 0028153951 scopus 로고
    • The phylogeny of proteinase 3/myeloblastin, the autoantigen in Wegener's granulomatosis, a myeloperoxidase as shown by immunohistochemical studies on human leukemia cell lines
    • Muller-Berat N, Minowada J, Tsuji-Takayama K, Drexler H, Lanotte M, Wieslander J et al. The phylogeny of proteinase 3/myeloblastin, the autoantigen in Wegener's granulomatosis, a myeloperoxidase as shown by immunohistochemical studies on human leukemia cell lines. Clin Immunol Immunopathol 1994; 70: 51-59.
    • (1994) Clin Immunol Immunopathol , vol.70 , pp. 51-59
    • Muller-Berat, N.1    Minowada, J.2    Tsuji-Takayama, K.3    Drexler, H.4    Lanotte, M.5    Wieslander, J.6
  • 21
    • 0024817730 scopus 로고
    • Down-regulation of a serine protease, myeloblastin, causes growth arrest and differentiation of promyelocytic leukemia cells
    • Bories D, Raynal MC, Solomon DH, Darzynkiewicz Z, Cayre YE. Down-regulation of a serine protease, myeloblastin, causes growth arrest and differentiation of promyelocytic leukemia cells. Cell 1989; 59: 959-968.
    • (1989) Cell , vol.59 , pp. 959-968
    • Bories, D.1    Raynal, M.C.2    Solomon, D.H.3    Darzynkiewicz, Z.4    Cayre, Y.E.5
  • 22
    • 0030997435 scopus 로고    scopus 로고
    • Granules of human neutrophilic polymorphonuclear leukocytes
    • Borregaard N, Cowland JB. Granules of human neutrophilic polymorphonuclear leukocytes. Blood 1997; 89: 3503-3521.
    • (1997) Blood , vol.89 , pp. 3503-3521
    • Borregaard, N.1    Cowland, J.B.2
  • 23
    • 0028077538 scopus 로고
    • T cell reactivity to proteinase 3 and myeloperoxidase in patients with Wegener's granulomatosis
    • Brouwer E, Stageman CA, Huitema MG, Limburg PC, Kallenberg CG. T cell reactivity to proteinase 3 and myeloperoxidase in patients with Wegener's granulomatosis. Clin Exp Immunol 1994; 98: 448-453.
    • (1994) Clin Exp Immunol , vol.98 , pp. 448-453
    • Brouwer, E.1    Stageman, C.A.2    Huitema, M.G.3    Limburg, P.C.4    Kallenberg, C.G.5
  • 25
    • 0029838112 scopus 로고    scopus 로고
    • Targeted T-cell therapy for human leukemia: Cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells
    • Molldrem J, Dermime S, Parker K, Jiang YZ, Mavroudis D, Hensel N et al. Targeted T-cell therapy for human leukemia: Cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood 1996; 88: 2450-2457.
    • (1996) Blood , vol.88 , pp. 2450-2457
    • Molldrem, J.1    Dermime, S.2    Parker, K.3    Jiang, Y.Z.4    Mavroudis, D.5    Hensel, N.6
  • 26
    • 0030841573 scopus 로고    scopus 로고
    • Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony forming units
    • Molldrem J, Clave E, Jiang YZ, Mavroudis D, Raptis A, Hensel N et al Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony forming units. Blood 1997; 90: 2529-2534.
    • (1997) Blood , vol.90 , pp. 2529-2534
    • Molldrem, J.1    Clave, E.2    Jiang, Y.Z.3    Mavroudis, D.4    Raptis, A.5    Hensel, N.6
  • 27
    • 0033152972 scopus 로고    scopus 로고
    • A PR1-human leukocyte antigen A2 tertramer can be used to isolate low frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chromic myelogenous leukemia
    • Molldrem JJ, Lee PP, Wang C, Champlin RE, Davis MM. A PR1-human leukocyte antigen A2 tertramer can be used to isolate low frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chromic myelogenous leukemia. Cancer Res 1999; 59: 2675-2681.
    • (1999) Cancer Res , vol.59 , pp. 2675-2681
    • Molldrem, J.J.1    Lee, P.P.2    Wang, C.3    Champlin, R.E.4    Davis, M.M.5
  • 28
    • 33746888125 scopus 로고    scopus 로고
    • Development of WT1 peptide cancer vaccine against hematopoietic malignancies and solid cancer
    • Oka Y, Tsuboi A, Kawakami M, Elisseeva OA, Nakajima H, Udaka K et al Development of WT1 peptide cancer vaccine against hematopoietic malignancies and solid cancer. Curr Med Chem 2006; 13: 2345-2352.
    • (2006) Curr Med Chem , vol.13 , pp. 2345-2352
    • Oka, Y.1    Tsuboi, A.2    Kawakami, M.3    Elisseeva, O.A.4    Nakajima, H.5    Udaka, K.6
  • 29
    • 0032522925 scopus 로고    scopus 로고
    • Wilms' tumor gene (WT1) competes with differentiation-inducing signal in hematopoietic progenitor cells
    • Inoue K, Tamaki H, Ogawa H, Oka Y, Soma T, Tatekawa T et al. Wilms' tumor gene (WT1) competes with differentiation-inducing signal in hematopoietic progenitor cells. Blood 1998; 91: 2969-2976.
    • (1998) Blood , vol.91 , pp. 2969-2976
    • Inoue, K.1    Tamaki, H.2    Ogawa, H.3    Oka, Y.4    Soma, T.5    Tatekawa, T.6
  • 30
    • 0032944068 scopus 로고    scopus 로고
    • Constitutive expression of the Wilms' tumor gene WT1 inhibits the differentiation of myeloid progenitor cells but promotes their proliferation in response to granulocyte-colony stimulating factor (G-CSF)
    • Tsuboi A, Oka Y, Ogawa H, Elisseeva OA, Tamaki H, Oji Y et al. Constitutive expression of the Wilms' tumor gene WT1 inhibits the differentiation of myeloid progenitor cells but promotes their proliferation in response to granulocyte-colony stimulating factor (G-CSF). Leuk Res 1999; 23: 499-505.
    • (1999) Leuk Res , vol.23 , pp. 499-505
    • Tsuboi, A.1    Oka, Y.2    Ogawa, H.3    Elisseeva, O.A.4    Tamaki, H.5    Oji, Y.6
  • 31
    • 0033966369 scopus 로고    scopus 로고
    • HLA class I-restricted lysis of leukemia cells by CD8+ cytotoxic T-lymphocyte clone specific for WT1 peptide
    • Ohminami H, Yasukawa M, Fujita S. HLA class I-restricted lysis of leukemia cells by CD8+ cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood 2000; 93: 286-293.
    • (2000) Blood , vol.93 , pp. 286-293
    • Ohminami, H.1    Yasukawa, M.2    Fujita, S.3
  • 32
    • 0034176750 scopus 로고    scopus 로고
    • Selective elimination of leukemia CD34+ progenitor cells by cytotoxic T lymphocytes specific for WT1
    • Gao L, Ballantuono I, Elsasser A, Marley SB, Gordon MY, Goldman JM et al. Selective elimination of leukemia CD34+ progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 2000; 95: 2198-2203.
    • (2000) Blood , vol.95 , pp. 2198-2203
    • Gao, L.1    Ballantuono, I.2    Elsasser, A.3    Marley, S.B.4    Gordon, M.Y.5    Goldman, J.M.6
  • 33
    • 0035577861 scopus 로고    scopus 로고
    • Equivalent induction of telomerase-specific cytotoxic T lymphocytes from tumor-bearing patients and healthy individuals
    • Vonderheide RH, Schultze JL, Anderson KS, maecker B, Butler MO, Xia Z et al. Equivalent induction of telomerase-specific cytotoxic T lymphocytes from tumor-bearing patients and healthy individuals. Cancer Res 2001; 61: 8366-8370.
    • (2001) Cancer Res , vol.61 , pp. 8366-8370
    • Vonderheide, R.H.1    Schultze, J.L.2    Anderson, K.S.3    maecker, B.4    Butler, M.O.5    Xia, Z.6
  • 34
    • 0035881885 scopus 로고    scopus 로고
    • Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients
    • Andersen MH, Pedersen LO, Capeller B, Bröker EB, Becker JC, thor Straten P. Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res 2001; 61 5964-5968.
    • (2001) Cancer Res , vol.61 , pp. 5964-5968
    • Andersen, M.H.1    Pedersen, L.O.2    Capeller, B.3    Bröker, E.B.4    Becker, J.C.5    thor Straten, P.6
  • 35
    • 0037818503 scopus 로고    scopus 로고
    • Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells
    • Schmidt SM, Schag K, Muller MR, Weck MM, Appel S, Kanz L et al. Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. Blood 2003; 102: 571-576.
    • (2003) Blood , vol.102 , pp. 571-576
    • Schmidt, S.M.1    Schag, K.2    Muller, M.R.3    Weck, M.M.4    Appel, S.5    Kanz, L.6
  • 36
    • 0031671357 scopus 로고    scopus 로고
    • Polymorphism in CD33 and CD34 genes: A source of minor histocompatibility antigens on haematopoietic progenitor cells?
    • Raptis A, Clave E, Mavroudis D, Molldrem J, Van Rhee F, Barrett AJ. Polymorphism in CD33 and CD34 genes: A source of minor histocompatibility antigens on haematopoietic progenitor cells? Br J Haematol 1998; 102: 1354-1358.
    • (1998) Br J Haematol , vol.102 , pp. 1354-1358
    • Raptis, A.1    Clave, E.2    Mavroudis, D.3    Molldrem, J.4    Van Rhee, F.5    Barrett, A.J.6
  • 37
    • 0037305594 scopus 로고    scopus 로고
    • Allorestricted cytotoxic T cells specific for human CD45 show potent antileukemic activity
    • Amrolia PJ, Reid SD, Gao, L, Schultheis B, Dotti G, Brenner MK et al Allorestricted cytotoxic T cells specific for human CD45 show potent antileukemic activity. Blood 2003; 101: 1007-1014.
    • (2003) Blood , vol.101 , pp. 1007-1014
    • Amrolia, P.J.1    Reid, S.D.2    Gao, L.3    Schultheis, B.4    Dotti, G.5    Brenner, M.K.6
  • 38
    • 0026645959 scopus 로고
    • A nanopeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigens MZ2-E
    • Traversari C, van der Bruggen P, Luescher IF, Lurquin C, Chomez P, Van Pel A et al. A nanopeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigens MZ2-E. J Exp Med 1992; 176: 1453-1457.
    • (1992) J Exp Med , vol.176 , pp. 1453-1457
    • Traversari, C.1    van der Bruggen, P.2    Luescher, I.F.3    Lurquin, C.4    Chomez, P.5    Van Pel, A.6
  • 39
    • 0028952240 scopus 로고
    • BAGE: A new gene encoding an antigen recognized on human melanoma by cytolytic T lymphocytes
    • Boel P, Wildmann C, Sensi ML, Brasseur R, Renauld JC, Coulie P et al BAGE: A new gene encoding an antigen recognized on human melanoma by cytolytic T lymphocytes. Immunity 1995; 2: 167-175.
    • (1995) Immunity , vol.2 , pp. 167-175
    • Boel, P.1    Wildmann, C.2    Sensi, M.L.3    Brasseur, R.4    Renauld, J.C.5    Coulie, P.6
  • 41
    • 0035883073 scopus 로고    scopus 로고
    • Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphocyte progression
    • Sotomayor EM, Borrello I, Rattis FM, Cuenca AG, Abrams J, Steveley-O'Carroll K et al. Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphocyte progression. Blood 2001; 98: 1070-1077.
    • (2001) Blood , vol.98 , pp. 1070-1077
    • Sotomayor, E.M.1    Borrello, I.2    Rattis, F.M.3    Cuenca, A.G.4    Abrams, J.5    Steveley-O'Carroll, K.6
  • 42
    • 0030319698 scopus 로고    scopus 로고
    • Tolerance and cancer: A critical issue in tumor immunology
    • Sotomayor EM, Borrello I, Levitsky HI. Tolerance and cancer: A critical issue in tumor immunology. Crit Rev Oncol 1996; 7: 433-456.
    • (1996) Crit Rev Oncol , vol.7 , pp. 433-456
    • Sotomayor, E.M.1    Borrello, I.2    Levitsky, H.I.3
  • 43
    • 0029870222 scopus 로고    scopus 로고
    • Specific human cellular immunity to bcr-abl oncogene-derived peptides
    • Bocchia M, Korontsvit T, Xu Q, Mackinnon S, Yang SY, Sette A et al Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood 1996; 87: 3587-3592.
    • (1996) Blood , vol.87 , pp. 3587-3592
    • Bocchia, M.1    Korontsvit, T.2    Xu, Q.3    Mackinnon, S.4    Yang, S.Y.5    Sette, A.6
  • 44
  • 45
    • 13844312036 scopus 로고    scopus 로고
    • Effect of p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: A multicentre observational trial
    • Bocchia M, Gentili S, Abruzzese E, Fanelli A, Iuliano F, Tabilio A et al. Effect of p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: A multicentre observational trial. Lancet 2005; 365: 657-662.
    • (2005) Lancet , vol.365 , pp. 657-662
    • Bocchia, M.1    Gentili, S.2    Abruzzese, E.3    Fanelli, A.4    Iuliano, F.5    Tabilio, A.6
  • 46
    • 0742324477 scopus 로고    scopus 로고
    • Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity
    • Mailaender V, Scheibenbogen C, Thiel E, Letsch A, Blau IW, Keilholz U. Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity. Leukemia 2004; 18: 165-166.
    • (2004) Leukemia , vol.18 , pp. 165-166
    • Mailaender, V.1    Scheibenbogen, C.2    Thiel, E.3    Letsch, A.4    Blau, I.W.5    Keilholz, U.6
  • 47
    • 51649126893 scopus 로고    scopus 로고
    • Letsch A, Scheibenbogen C, Busse A, Asemissen A, Schmittel WK, Hofmann L et al. Phase II trial of vaccination with WT1 peptide, GM-CSF, and KHL in patients with acute myeloid leukemia and myelodysplasia: Final immunological, molecular, and clinical results. Abstract J Clin Oncol 2007; 25: 3800 (Abstract No. 3008).
    • Letsch A, Scheibenbogen C, Busse A, Asemissen A, Schmittel WK, Hofmann L et al. Phase II trial of vaccination with WT1 peptide, GM-CSF, and KHL in patients with acute myeloid leukemia and myelodysplasia: Final immunological, molecular, and clinical results. Abstract J Clin Oncol 2007; 25: 3800 (Abstract No. 3008).
  • 48
    • 20444448873 scopus 로고    scopus 로고
    • Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein and chronic myelogenous leukemia
    • Li Z, Qiao Y, Liu B, Laska EJ, Chakravarthi P, Kulko JM et al. Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein and chronic myelogenous leukemia. Clin Cancer Res 2005; 11: 4460-4468.
    • (2005) Clin Cancer Res , vol.11 , pp. 4460-4468
    • Li, Z.1    Qiao, Y.2    Liu, B.3    Laska, E.J.4    Chakravarthi, P.5    Kulko, J.M.6
  • 49
    • 0028179056 scopus 로고
    • Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens
    • Huang AY, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 1994; 264: 961-965.
    • (1994) Science , vol.264 , pp. 961-965
    • Huang, A.Y.1    Golumbek, P.2    Ahmadzadeh, M.3    Jaffee, E.4    Pardoll, D.5    Levitsky, H.6
  • 50
    • 0029864363 scopus 로고    scopus 로고
    • Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo?
    • Huang AY, Bruce AT, Pardoll DM, Levitsky H. Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo? J Exp Med 1996; 183: 769-776.
    • (1996) J Exp Med , vol.183 , pp. 769-776
    • Huang, A.Y.1    Bruce, A.T.2    Pardoll, D.M.3    Levitsky, H.4
  • 51
    • 0027538181 scopus 로고
    • Vaccination with irradiated tumor cells engineered to express granulocyte-macrophage colony stimulating factor stimulates potent, specific, and long-lasting antitumor immunity
    • Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K et al Vaccination with irradiated tumor cells engineered to express granulocyte-macrophage colony stimulating factor stimulates potent, specific, and long-lasting antitumor immunity. Proc Natl Acad Sci USA 1993; 90: 3539-3543.
    • (1993) Proc Natl Acad Sci USA , vol.90 , pp. 3539-3543
    • Dranoff, G.1    Jaffee, E.2    Lazenby, A.3    Golumbek, P.4    Levitsky, H.5    Brose, K.6
  • 52
    • 0029963944 scopus 로고    scopus 로고
    • Immunization with granulocyte-macrophage colony stimulating factor transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific immune responses and generates potent systemic antitumor immunity
    • evitsky HI, Montgomery J, Ahmedzahed M, Staveley-O'Carroll K, Guarnieri F, Longo DM et al. Immunization with granulocyte-macrophage colony stimulating factor transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific immune responses and generates potent systemic antitumor immunity. J Immunol 1996; 156: 3858-3865.
    • (1996) J Immunol , vol.156 , pp. 3858-3865
    • evitsky, H.I.1    Montgomery, J.2    Ahmedzahed, M.3    Staveley-O'Carroll, K.4    Guarnieri, F.5    Longo, D.M.6
  • 53
    • 0033543076 scopus 로고    scopus 로고
    • A universal granulocyte-macrophage colony stimulating factor-producing by-stander cell line for the use in the formulation of formulation of tumor cell based vaccines
    • Borrello I, Sotomayor EM, Cooke S, Levitsky H. A universal granulocyte-macrophage colony stimulating factor-producing by-stander cell line for the use in the formulation of formulation of tumor cell based vaccines. Hum Gene Ther 1999; 10: 1983-1991.
    • (1999) Hum Gene Ther , vol.10 , pp. 1983-1991
    • Borrello, I.1    Sotomayor, E.M.2    Cooke, S.3    Levitsky, H.4
  • 54
    • 51649098640 scopus 로고    scopus 로고
    • Smith BD, Kasamon YL, Miller CB, Chia CY, Murphy K, Kowalski J et al K562/GM-CSF vaccination reduces tumor burden, including achieving molecular remissions, in chronic myeloid leukemia (CML) patients with residual disease on imatinib mesylate (IM). American society of hematology annual meeting. Blood 2005; 106: 801 a (Abstract No. 6509).
    • Smith BD, Kasamon YL, Miller CB, Chia CY, Murphy K, Kowalski J et al K562/GM-CSF vaccination reduces tumor burden, including achieving molecular remissions, in chronic myeloid leukemia (CML) patients with residual disease on imatinib mesylate (IM). American society of hematology annual meeting. Blood 2005; 106: 801 a (Abstract No. 6509).
  • 55
    • 34848865393 scopus 로고    scopus 로고
    • T-cell therapy after hematopoietic stem cell transplantation
    • Kennedy-Nasser AA, Brenner MK. T-cell therapy after hematopoietic stem cell transplantation. Curr Opin Hematol 2007; 14: 616-624.
    • (2007) Curr Opin Hematol , vol.14 , pp. 616-624
    • Kennedy-Nasser, A.A.1    Brenner, M.K.2
  • 57
    • 33745504341 scopus 로고    scopus 로고
    • Function of natural killer cells in immune defense against human leukemia
    • Wodnar-Filipowicz A, Kalberer CP. Function of natural killer cells in immune defense against human leukemia. Swiss Med Wkly 2006; 136 359-364.
    • (2006) Swiss Med Wkly , vol.136 , pp. 359-364
    • Wodnar-Filipowicz, A.1    Kalberer, C.P.2
  • 58
    • 33646794392 scopus 로고    scopus 로고
    • Checkpoint blockade in cancer immunotherapy
    • Korman AJ, Peggs KS, Allison JP. Checkpoint blockade in cancer immunotherapy. Adv Immunol 2006; 90: 297-339.
    • (2006) Adv Immunol , vol.90 , pp. 297-339
    • Korman, A.J.1    Peggs, K.S.2    Allison, J.P.3
  • 59
    • 34548585368 scopus 로고    scopus 로고
    • The use of hypomethylating agents in the treatment of hematological malignancies
    • Kihslinger JE, Godley LA. The use of hypomethylating agents in the treatment of hematological malignancies. Leuk Lymphoma 2007; 48 1676-1695.
    • (2007) Leuk Lymphoma , vol.48 , pp. 1676-1695
    • Kihslinger, J.E.1    Godley, L.A.2
  • 60
    • 33847216496 scopus 로고    scopus 로고
    • Vascular endothelial growth factor and its receptors as drug targets in hematological malignancies
    • Kessler T, Fehrmann F, Bieker R, Berdel WE, Mesters RM. Vascular endothelial growth factor and its receptors as drug targets in hematological malignancies. Curr Drug Targets 2007; 8: 257-268.
    • (2007) Curr Drug Targets , vol.8 , pp. 257-268
    • Kessler, T.1    Fehrmann, F.2    Bieker, R.3    Berdel, W.E.4    Mesters, R.M.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.